Waiting for Traumakine data tests edgy investors' patience

8 May 2017

Faron Pharmaceuticals (AIM: FARN) has received a monitoring committee report into its Phase III Traumakine (recombinant human interferon beta-1a) study.

The Finnish biopharma company revealed sparse detail from the report. Fearing the worst, edgy investors oversaw a 25% slump in the company’s stock price in London today.

Faron says the independent data monitoring committee has recommended the trial should continue as planned.

The committee will provide its next recommendation after reviewing the data at 240 recruited patients, which is expected in the third quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK